<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463357</url>
  </required_header>
  <id_info>
    <org_study_id>15-0254</org_study_id>
    <nct_id>NCT02463357</nct_id>
  </id_info>
  <brief_title>Three New Ideas to Protect Special Forces From the Stress of High Altitude</brief_title>
  <official_title>Three New Ideas to Protect Special Forces From the Stress of High Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alma College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of&#xD;
      non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric&#xD;
      pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS.&#xD;
      Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and&#xD;
      difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance&#xD;
      and endurance exercise capacity are impaired. Therefore, the goal of this research is to&#xD;
      identify effective pharmacological agents that will help reduce the symptoms of AMS and&#xD;
      improve physical and cognitive performance at high altitude.&#xD;
&#xD;
      The investigators will study the efficacy of the dietary supplement, quercetin, the drugs&#xD;
      nifedipine (extended release) and methazolamide taken together, the drug metformin, and the&#xD;
      drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at&#xD;
      high altitudes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Environmental Symptoms Questionnaire at High Altitude</measure>
    <time_frame>Baseline and during high altitude exposure (3 days, AM/PM)</time_frame>
    <description>Self-reported assessment of AMS symptoms (headache, lightheaded, dizzy, etc.). The 11-item Environmental Symptoms Questionnaire measures Acute Mountain Sickness symptoms (nausea, weakness, lightheadedness, dizziness, headache, etc.). Possible scores range from 0 to 55 (0-5 per item), with higher scores indicating a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lake Louise AMS Scoring System at High Altitude</measure>
    <time_frame>Baseline and during high altitude exposure (3 days, AM/PM)</time_frame>
    <description>Self-reported assessment of AMS symptoms (headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping). The Lake Louise AMS Scoring System measures symptoms of altitude sickness. Possible scores range from 0 to 16, with higher scores indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Army Physical Fitness Test (APFT) at High Altitude</measure>
    <time_frame>Baseline, 1st day at high altitude</time_frame>
    <description>Timed 2 mile run, push-ups, sit-ups, and pull-ups. The Army Physical Fitness Test (APFT) measures physical fitness. Higher scores indicate a better outcome. A score of 60 is considered minimum &quot;passing&quot; score. The maximum possible score is 300, indicating the highest level of physical fitness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Uphill Hike at High Altitude</measure>
    <time_frame>2nd day at altitude</time_frame>
    <description>Timed 3.1 mile uphill run/hike, with weighted back-pack</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude</measure>
    <time_frame>Baseline and and 1st day at high altitude</time_frame>
    <description>Battery of nine cognitive function tests. The Defense Automated Neurobehavioral Assessment (DANA) measures cognitive function and was used to measure mean reaction time. Possible scores range from 180 to 500 milliseconds, with lower scores indicating a better outcome.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Mountain Sickness</condition>
  <arm_group>
    <arm_group_label>Quercetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quercetin: 500mg pill, twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine+Methazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill manufactured to look like all other investigational products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitrite: 20mg pill, three times daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <arm_group_label>Quercetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine extended release</intervention_name>
    <arm_group_label>Nifedipine+Methazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methazolamide</intervention_name>
    <arm_group_label>Nifedipine+Methazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrite</intervention_name>
    <arm_group_label>Nitrite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy,&#xD;
&#xD;
          -  young (18-30 years old) men who can meet APFT requirements for special operation&#xD;
             forces (SOF) training as outlined by the US Army (42 push ups, 53 sit-ups, 6 pull-ups,&#xD;
             2 mile run in &lt; 15 min 54 s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women;&#xD;
&#xD;
          -  smokers;&#xD;
&#xD;
          -  participants with diseases or disorders known to be affected by hypoxia or the drugs&#xD;
             used in this study, such as hypotension, anemia, sickle cell trait or disease, and&#xD;
             diabetes;&#xD;
&#xD;
          -  participants with a history of significant head injury, migraines or seizures;&#xD;
&#xD;
          -  participants taking any medication (over-the-counter or prescription) or herbal&#xD;
             supplements;&#xD;
&#xD;
          -  participants with known flavonoid allergies;&#xD;
&#xD;
          -  participants with known allergies to metformin;&#xD;
&#xD;
          -  participants with known hypersensitivity reaction to nifedipine;&#xD;
&#xD;
          -  participants with known allergies to sulfonamide-based drugs;&#xD;
&#xD;
          -  participants with inability to be headache-free when consuming the amount of caffeine&#xD;
             in two six ounce cups of coffee or less per day;&#xD;
&#xD;
          -  exposure to high altitude above 1000m in the previous three months; or&#xD;
&#xD;
          -  participants who have been on an airline flight over six hours (the lowered cabin&#xD;
             pressure for an extended period of time approximates exposure to high altitude);&#xD;
&#xD;
          -  participants who are unable to achieve the minimum physical criteria required for SOF&#xD;
             training&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Roach, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Anschutz Medical Campus, Altitude Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alma College</name>
      <address>
        <city>Alma</city>
        <state>Michigan</state>
        <zip>48801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>March 4, 2021</results_first_submitted>
  <results_first_submitted_qc>March 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise, Aerobic</keyword>
  <keyword>Cognitive Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Methazolamide</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>49 participants were excluded after consent/enrollment but prior to starting the study because some subjects did not meet baseline criteria, and others had to be excluded due to resource limitations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quercetin</title>
          <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
        </group>
        <group group_id="P2">
          <title>Nifedipine+Methazolamide</title>
          <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
        </group>
        <group group_id="P3">
          <title>Metformin</title>
          <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
        </group>
        <group group_id="P5">
          <title>Nitrite</title>
          <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quercetin</title>
          <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
        </group>
        <group group_id="B2">
          <title>Nifedipine+Methazolamide</title>
          <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
        </group>
        <group group_id="B3">
          <title>Metformin</title>
          <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Nitrite</title>
          <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="3.0"/>
                    <measurement group_id="B2" value="21.9" spread="2.6"/>
                    <measurement group_id="B3" value="21.7" spread="2.0"/>
                    <measurement group_id="B4" value="21.3" spread="1.4"/>
                    <measurement group_id="B5" value="22.0" spread="2.1"/>
                    <measurement group_id="B6" value="21.9" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Environmental Symptoms Questionnaire at High Altitude</title>
        <description>Self-reported assessment of AMS symptoms (headache, lightheaded, dizzy, etc.). The 11-item Environmental Symptoms Questionnaire measures Acute Mountain Sickness symptoms (nausea, weakness, lightheadedness, dizziness, headache, etc.). Possible scores range from 0 to 55 (0-5 per item), with higher scores indicating a better outcome.</description>
        <time_frame>Baseline and during high altitude exposure (3 days, AM/PM)</time_frame>
        <population>Two participants who withdrew from the study were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin</title>
            <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine+Methazolamide</title>
            <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
          </group>
          <group group_id="O5">
            <title>Nitrite</title>
            <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Environmental Symptoms Questionnaire at High Altitude</title>
          <description>Self-reported assessment of AMS symptoms (headache, lightheaded, dizzy, etc.). The 11-item Environmental Symptoms Questionnaire measures Acute Mountain Sickness symptoms (nausea, weakness, lightheadedness, dizziness, headache, etc.). Possible scores range from 0 to 55 (0-5 per item), with higher scores indicating a better outcome.</description>
          <population>Two participants who withdrew from the study were not analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.179"/>
                    <measurement group_id="O2" value="0.122" spread="0.214"/>
                    <measurement group_id="O3" value="0.080" spread="0.132"/>
                    <measurement group_id="O4" value="0.069" spread="0.109"/>
                    <measurement group_id="O5" value="0.121" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.088" spread="0.214"/>
                    <measurement group_id="O2" value="-0.073" spread="0.224"/>
                    <measurement group_id="O3" value="0.128" spread="0.425"/>
                    <measurement group_id="O4" value="0.035" spread="0.184"/>
                    <measurement group_id="O5" value="0.044" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Lake Louise AMS Scoring System at High Altitude</title>
        <description>Self-reported assessment of AMS symptoms (headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping). The Lake Louise AMS Scoring System measures symptoms of altitude sickness. Possible scores range from 0 to 16, with higher scores indicating a worse outcome.</description>
        <time_frame>Baseline and during high altitude exposure (3 days, AM/PM)</time_frame>
        <population>Two participants who withdrew from the study were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin</title>
            <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine+Methazolamide</title>
            <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
          </group>
          <group group_id="O5">
            <title>Nitrite</title>
            <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lake Louise AMS Scoring System at High Altitude</title>
          <description>Self-reported assessment of AMS symptoms (headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping). The Lake Louise AMS Scoring System measures symptoms of altitude sickness. Possible scores range from 0 to 16, with higher scores indicating a worse outcome.</description>
          <population>Two participants who withdrew from the study were not analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.150" spread="0.489"/>
                    <measurement group_id="O3" value="0.150" spread="0.671"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.250" spread="1.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.229"/>
                    <measurement group_id="O2" value="0.150" spread="0.875"/>
                    <measurement group_id="O3" value="0.750" spread="2.124"/>
                    <measurement group_id="O4" value="0.632" spread="1.012"/>
                    <measurement group_id="O5" value="0.474" spread="1.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Army Physical Fitness Test (APFT) at High Altitude</title>
        <description>Timed 2 mile run, push-ups, sit-ups, and pull-ups. The Army Physical Fitness Test (APFT) measures physical fitness. Higher scores indicate a better outcome. A score of 60 is considered minimum &quot;passing&quot; score. The maximum possible score is 300, indicating the highest level of physical fitness.</description>
        <time_frame>Baseline, 1st day at high altitude</time_frame>
        <population>Two participants who withdrew from the study were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin</title>
            <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine+Methazolamide</title>
            <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
          </group>
          <group group_id="O5">
            <title>Nitrite</title>
            <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Army Physical Fitness Test (APFT) at High Altitude</title>
          <description>Timed 2 mile run, push-ups, sit-ups, and pull-ups. The Army Physical Fitness Test (APFT) measures physical fitness. Higher scores indicate a better outcome. A score of 60 is considered minimum &quot;passing&quot; score. The maximum possible score is 300, indicating the highest level of physical fitness.</description>
          <population>Two participants who withdrew from the study were not analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.2" spread="25.1"/>
                    <measurement group_id="O2" value="251.0" spread="29.4"/>
                    <measurement group_id="O3" value="254.1" spread="26.9"/>
                    <measurement group_id="O4" value="251.5" spread="23.9"/>
                    <measurement group_id="O5" value="252.1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="23.1"/>
                    <measurement group_id="O2" value="-59.2" spread="22.7"/>
                    <measurement group_id="O3" value="-32.9" spread="20.5"/>
                    <measurement group_id="O4" value="-23.0" spread="27.0"/>
                    <measurement group_id="O5" value="-26.1" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Uphill Hike at High Altitude</title>
        <description>Timed 3.1 mile uphill run/hike, with weighted back-pack</description>
        <time_frame>2nd day at altitude</time_frame>
        <population>Two participants who withdrew from the study were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin</title>
            <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine+Methazolamide</title>
            <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
          </group>
          <group group_id="O5">
            <title>Nitrite</title>
            <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Uphill Hike at High Altitude</title>
          <description>Timed 3.1 mile uphill run/hike, with weighted back-pack</description>
          <population>Two participants who withdrew from the study were not analyzed.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4685" spread="364.4"/>
                    <measurement group_id="O2" value="4993" spread="595.4"/>
                    <measurement group_id="O3" value="5005" spread="975.9"/>
                    <measurement group_id="O4" value="4819" spread="685.1"/>
                    <measurement group_id="O5" value="4953" spread="670.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude</title>
        <description>Battery of nine cognitive function tests. The Defense Automated Neurobehavioral Assessment (DANA) measures cognitive function and was used to measure mean reaction time. Possible scores range from 180 to 500 milliseconds, with lower scores indicating a better outcome.</description>
        <time_frame>Baseline and and 1st day at high altitude</time_frame>
        <population>Seven participants were not analyzed due to lack of data collection at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Quercetin</title>
            <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine+Methazolamide</title>
            <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
          </group>
          <group group_id="O5">
            <title>Nitrite</title>
            <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude</title>
          <description>Battery of nine cognitive function tests. The Defense Automated Neurobehavioral Assessment (DANA) measures cognitive function and was used to measure mean reaction time. Possible scores range from 180 to 500 milliseconds, with lower scores indicating a better outcome.</description>
          <population>Seven participants were not analyzed due to lack of data collection at baseline.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.0" spread="34.7"/>
                    <measurement group_id="O2" value="302.2" spread="49.5"/>
                    <measurement group_id="O3" value="312.3" spread="46.1"/>
                    <measurement group_id="O4" value="333.9" spread="41.5"/>
                    <measurement group_id="O5" value="310.7" spread="29.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="27.8"/>
                    <measurement group_id="O2" value="14.2" spread="26.6"/>
                    <measurement group_id="O3" value="-8.3" spread="37.9"/>
                    <measurement group_id="O4" value="0.5" spread="30.6"/>
                    <measurement group_id="O5" value="-4.6" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quercetin</title>
          <description>Quercetin: 500mg pill, twice daily for 5 days&#xD;
Quercetin</description>
        </group>
        <group group_id="E2">
          <title>Nifedipine+Methazolamide</title>
          <description>Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days&#xD;
Nifedipine extended release&#xD;
Methazolamide</description>
        </group>
        <group group_id="E3">
          <title>Metformin</title>
          <description>Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)&#xD;
Metformin</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Sugar pill manufactured to look like all other investigational products&#xD;
Placebo</description>
        </group>
        <group group_id="E5">
          <title>Nitrite</title>
          <description>Nitrite: 20mg pill, three times daily for 5 days&#xD;
Nitrite</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URI/ILI (Flu-like illness)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety attack</sub_title>
                <description>Anxiety attack upon arrival at venue (participant had previous history of anxiety)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Roach</name_or_title>
      <organization>University of Colorado Denver</organization>
      <email>clinicalresearchsupportcenter@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

